Soligenix
NEWS
The FDA has rejected Soligenix’s NDA for HyBryte (synthetic hypericin), a therapeutic developed to treat early-stage cutaneous T-cell lymphoma.
There is some evidence that COVID-19 infection might be linked to an increase in diabetes, particularly Type 1 diabetes, which is an autoimmune disease most commonly diagnosed in children.
The two posters outlining ongoing formulation efforts to develop a trivalent thermostabilized Ebola vaccine presented on Wednesday July 31 at the 2019 Colorado Protein Stability Conference are now available.
Soligenix, Inc. announced that Soligenix will be participating in a biodefense contract for the development of medical countermeasures against bacterial threat agents, with Soligenix awarded a subcontract of approximately $600,000 over 3 years.
Soligenix, Inc. announced its recent accomplishments and financial results for the quarter ended March 31, 2019.
In this interview, Dr. Christopher J. Schaber, President and CEO, discusses the Company with The Wall Street Analyzer.
Soligenix, Inc. issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.
Soligenix, Inc announced its recent accomplishments and financial results for the year ended December 31, 2018.
Soligenix, Inc. announced that they will be presenting at the National Institutes of Health - Commercialization Accelerator Program “FeedForward Session” in Washington, DC on March 21, 2019.
JOBS
IN THE PRESS